Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Stomach Neoplasms
Interventions: DRUG: Herceptin|DRUG: afatinib|DRUG: trastuzumab|DRUG: Herceptin|DRUG: afatinib|DRUG: afatinib
Sponsor: Boehringer Ingelheim